T-cell epitopes identified by BALB/c mice immunized with vaccinia expressing HIV-1 gag lie within immunodominant regions recognized by HIV-infected Indian patients

Journal of Global Infectious Diseases

Volumn 3, Issue 3, 2011, Pages 246-253

  Shete, Ashwini V ^a   Thakar, Madhuri R ^a   Tripathy, Srikanth P ^a   Raut, C G ^b   Chakrabarti, Sekhar ^c   Paranjape, Ramesh S ^a  

^a Department of Immunology and Molecular Virology ^*  (India)

^b NATIONAL INSTITUTE OF VIROLOGY   (India)

^c NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

Cellular immune response; T cell epitopes; Vgag

Indexed keywords

ANTI P24 ANTIBODY; ANTIGEN P24; EPITOPE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS 1 GAG ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL SECRETION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; FEMALE; GENE CONSTRUCT; GENE SEQUENCE; GROUP SPECIFIC ANTIGEN GENE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INTERFERON PRODUCTION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINANT;

EID: 80051866621     PISSN: 0974777X     EISSN: 09748245     Source Type: Journal    
DOI: 10.4103/0974-777X.83530     Document Type: Article

References (30)

1. Department of AIDS control, Ministry of Health and family welfare, Annual report 2009-2010. Available form: http://www.nacoonline.org/upload/AR%202009- 10/NACO-AR-English%20 corrected.pdf [Last cited on 2010,Nov 25].
2. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
3. Kittikraisak W, van Griensven F, Martin M, McNicholl J, Gilbert PB, Chuachoowong R, et al. Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr 2009;51:601-8.
4. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-72.
5. Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, Walker BD, et al. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term non progressor: Constraints on immune escape associated with targeting a sequence essential for viral replication. J Immunol 1999;162:3727-34. (Pubitemid 29313630)
6. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT, et al. Gag-Specific CD8 + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007;178:2746-54. (Pubitemid 46333151)
7. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002;28:2354-60. (Pubitemid 34734202)
8. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303:2019-22. (Pubitemid 38393277)
9. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG-T, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004;85:911-9. (Pubitemid 38489556)
10. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
11. Kurle S, Tripathi S, Jadhav S, Agnihotri K, Paranjape R. Full-Length gag sequences of HIV Type 1 Subtype C recent seroconverters from Pune, India. AIDS Res Hum Retrovir 2004;20:1113-8. (Pubitemid 39392016)
12. Chakrabarti S, Sisler J R, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 1997;23:1094-7. (Pubitemid 27523268)
13. Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW. Preparation of cell cultures and Vaccinia virus stocks: Curr Protoc Mol Boil 1993;24(Supplement 15): 16.16.1-5.
14. Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, et al. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 gag and Nef. J Infect Dis 2005;192:749-59. (Pubitemid 41193072)
15. Ramírez JC, Gherardi MM, Esteban M. Biology of attenuated modified Vaccinia Virus Ankara recombinant vector in mice: Virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J virol 2000;74:923.
16. Ramírez JC, Gherardi MM, Rodrguez D, Esteban M. Attenuated modified vaccinia virus ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000;74:7651-5. (Pubitemid 30613113)
17. Robinson HL, Weinhold KJ. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. J Infect Dis 2006;194:1625-7. (Pubitemid 44901990)
18. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 1999;96:4512-7 (Pubitemid 29190367)
19. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, García-Sastre A. Optimization of human immunodeficiency virus gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009;83:584-97.
20. Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, et al. Apoptotic death of CD81 T lymphocytes after immunization: induction of a suppressive population of Mac-11/Gr-11 Cells. J Immunol 1998;161:5313-20. (Pubitemid 28519091)
21. Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, et al. Different patterns of immune responses but similar control of simian immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002;75:7625-31 (Pubitemid 34760986)
22. Hutchings CL, Gilbert SC, Hill AV, Moore AC. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 2005;175:599-606. (Pubitemid 40884366)
23. Cellini S, Fortini C, Gallerani E, Destro F, Cofano EB, Caputo A, et al. Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice Virol J 2008;5:81.
24. Kumar S, Seth P. Immunogenicity of recombinant modified vaccinia ankara viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice. Viral Immunol 2004;17:574-9. (Pubitemid 40054237)
25. Novitsky V, Rybak N, McLane MF, Gilbert P, Chigwedere P, Klein I, et al. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001;75:9210-28. (Pubitemid 32851925)
26. Gupta RM, Prasad VV, Rai A, Seth P. Analysis of HIV Type 1 Subtype C full-length gag gene sequences from India: Novel observations and plausible implications. AIDS Res Hum Retrovir 2005;21:1066-72. (Pubitemid 43069192)
27. Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, Bishop K, Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 2008;3:e1424.
28. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 2002;168:5499-506. (Pubitemid 34556128)
29. Geels MJ, Dubey SA, Anderson K, Baan E, Bakker M, Pollakis G, et al. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus Type 1 non-B clades (A to G): Importance of HLA anchor residue conservation. J Virol 2005;79:11247-58. (Pubitemid 41170667)
30. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, et al. Consistent cytotoxic-T-lymphocyte targeting of Immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004;78:2187-200. (Pubitemid 38228912)